Poll Results

July 2018 Question of the Month

What is your opinion on pharmacists being allowed to refuse to dispense a prescription for ethical reasons?

Agree: 12.5%

Agree, if they can find another reasonable option for the patient: 56.25%

Disagree: 25%

Indifferent: 6.25%

June 2018 Question of the Month

Do you feel that disclosing the list price of prescription drugs during DTC ads will decrease patient demand for certain products?

Yes: 14.3%

No: 85.7%

May 2018 Question of the Month

Are pharmacists’ licenses at risk when dispensing medical marijuana, a DEA Schedule I substance?

Yes: 66.7%

No: 33.3%

April 2018 Question of the Month

Which of these do you expect to create the biggest buzz in 2018?

Biosimilar availability: 11.0%

Clawbacks or DIR fees: 27.8%

Copay cards for generic drugs: 5.6%

Mergers in healthcare: 50.0%

Outcomes-based agreements: 5.6%

March 2018 Question of the Month

Which of the following best describes how you were affected by the 2017-2018 flu season?

Received the flu vaccine, did not get the flu: 58.33%
Received the flu vaccine, did get the flu: 8.33%
Did not receive the flu vaccine, did not get the flu: 16.67%
Did not receive the flu vaccine, did get the flu: 16.67%

 

Do you plan to receive the flu vaccine for next flu season?

Yes: 70%
No: 30%

February 2018 Question of the Month

What is the biggest challenge faced by pharmacists today?

Drug shortages: 9.52%

Reimbursement for clinical services: 0%

Staff shortages/long working hours: 23.81%

Managing patient prescription coverage: 4.76%

Reimbursement for prescriptions: 57.14%

Verifying prescription orders/instructions: 0%

None of these: 4.76%

January Question of the Month

Should physicians be required to participate in mandatory education on opioids as part of ongoing attempts to limit opioid addiction?

Yes: 100%

No: 0%

December Question of the Month

When authorized generics are introduced to the market without any generic competition, does this help reduce payer cost and improve pharmacy margins?

Yes: 11.2%

No: 0%

Generally yes, but depends on pricing of AG and whether it’s reimbursed as a brand or generic: 44.4%

Generally no, but payer rebates and pharmacy discounts may help: 44.4%

November Question of the Month

Which of the following will be the most limiting factor for manufacturers to use the FDA’s guidance documents in the development of “complex generic drugs”?

Limited time and resources of the FDA: 0%

High cost of developing complex generic drugs: 25%

Low return on investment: 25%

Complex clinical testing to prove equivalence: 50%

None of these: 0%

October Question of the Month

Are you in favor of allowing US residents to import prescription drugs from abroad?

Yes: 42.9%

No: 57.1%